A tetracycline-inducible and skeletal muscle-specific Cre recombinase transgenic mouse.
We have generated a transgenic mouse that expresses Cre recombinase only in skeletal muscle and only following tetracycline treatment. This spatiotemporal specificity is achieved using two transgenes. The first transgene uses the human skeletal actin (HSA) promoter to drive expression of the reverse tetracycline-controlled transactivator (rtTA). The second transgene uses a tetracycline responsive promoter to drive the expression of Cre recombinase. We monitored transgene expression in these mice by crossing them with ROSA26 loxP-LacZ reporter mice, which express beta-galactosidase when activated by Cre. We find that the expression of this transgene is only detectable within skeletal muscle and that Cre expression in the absence of tetracycline is negligible. Cre is readily induced in this model with tetracycline analogs at a range of embryonic and postnatal ages and in a pattern consistent with other HSA transgenic mice. This mouse improves upon existing transgenic mice in which skeletal muscle Cre is expressed throughout development by allowing Cre expression to begin at later developmental stages. This temporal control of transgene expression has several applications, including overcoming embryonic or perinatal lethality due to transgene expression. This mouse is especially suited for studies of steroid hormone action, as it uses tetracycline, rather than tamoxifen, to activate Cre expression. In summary, we find that this transgenic induction system is suitable for studies of gene function in the context of hormonal regulation of skeletal muscle or interactions between muscle and motoneurons in mice.
Rao
Pengcheng
P
Department of Psychology, University of Toronto Mississauga, Mississauga, ON L5L 1C6, Canada.
Monks
D Ashley
DA
D000199:Actins / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D004622:Embryo, Mammalian; D005697:Galactosides / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects*; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects; D006801:Humans; D019426:Integrases / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008822:Mice, Transgenic; D018482:Muscle, Skeletal / Q000378:metabolism*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D011506:Proteins / Q000235:genetics / Q000378:metabolism; D022661:RNA, Untranslated; D011995:Recombination, Genetic / Q000187:drug effects* / Q000502:physiology; D013752:Tetracycline / Q000494:pharmacology*
D000199:Actins; D005697:Galactosides; C110853:Gt(ROSA)26Sor non-coding RNA, mouse; D011500:Protein Synthesis Inhibitors; D011506:Proteins; D022661:RNA, Untranslated; C007816:beta-galactoside; C045073:Cre recombinase; D019426:Integrases; D013752:Tetracycline